‘Uber for Getting Off Antidepressants' Launches in the US
Jun 10, 2025 6:00 AM Outro, which is now available in seven states, wants to help people taper off antidepressants without experiencing debilitating side effects.
Ariella Sharf was first prescribed antidepressants when she was a college student more than a decade ago. When she decided to stop taking them last year, Sharf says she wasn't sure how to do it safely. She was disappointed when her longtime psychiatrist didn't help her find a new doctor after she moved across the country, and she thought her primary care physician wasn't equipped for the task. Sharf decided instead to try Outro Health, a telehealth startup that CEO and cofounder Brandon Goode describes as 'Uber for getting off antidepressants.'
Outro officially launched in the US last month and is currently available in seven states, including California and New York. The startup is betting that many of the growing number of Americans taking antidepressants will eventually want help coming off them. Over 11 percent of US adults took medication for depression in 2023, according to the US Centers for Disease Control and Prevention's National Health Interview Survey, which found women were more than twice as likely as men to use the drugs.
About one in six people who stop taking antidepressants experience side effects like nausea and dizziness, especially if they do so abruptly, according to one study. Other research has found the prevalence of adverse withdrawal symptoms may be much higher, particularly among patients who have been on them for long periods.
For a monthly fee starting at $125, Outro pairs patients with a clinician who meets with them on a custom schedule—often weekly or monthly—and guides them through a tailored tapering program. Outro currently employs a small group of medical contractors, including nurse practitioners specializing in psychiatry and general nurse practitioners, who are supervised by psychiatrists. For now, patients pay for the service entirely out of pocket, but Goode says Outro plans to start accepting insurance soon.
Outro's program is currently focused specifically on drugs often prescribed for depression, including selective serotonin reuptake inhibitors (SSRIs) like Lexapro and Prozac, and serotonin–norepinephrine reuptake inhibitors (SNRIs) like Pristiq and Cymbalta. In the next year, Goode says, the company is planning to expand beyond antidepressants and begin offering tapering programs for stimulants and benzodiazepines, two classes of drug that are commonly prescribed in the US for issues like anxiety and ADHD and are known to cause intense withdrawal symptoms.
'I was kind of waiting for something like Outro to exist,' says Sharf, who became one of the company's first patients in the United States last June as part of a pilot program in California. 'Everything was tailored around how I wanted to do it.' Twelve months later, Sharf says she is still tapering off her medication with help from Outro at a pace that works for her.
When customers sign up for Outro and get matched with clinicians, they then typically follow a tapering method endorsed by one of Outro's other cofounders, the British academic psychiatrist Mark Horowitz. Known as 'hyperbolic tapering,' it's a substantially more drawn-out process than other methods used to help people get off meds.
Unlike a linear taper, which involves reducing the dose of a medication by the same amount each time, a hyperbolic taper gradually slows the rate of reduction—cutting smaller and smaller amounts as it goes—so that the final doses are extremely small and spread out over a much longer period. To facilitate this, Outro partners with compounding pharmacies to produce custom versions of generic antidepressants in minuscule doses that are not available commercially. In other words, while Outro promotes itself as a service for getting off medication, part of its business model hinges on people continuing to take the compounded drugs its clinicians prescribe.
Horowitz, who has become one of the UK's leading experts on medication tapering, known as de-prescribing, says his interest in the topic was driven by his own harrowing experience coming off antidepressants more than a decade ago when he was a psychiatry doctoral student. Horowitz crafted a gradual tapering plan for himself that involved using syringes from his research lab to dole out small liquid doses of escitalopram, known by the brand name Lexapro. But he couldn't prevent the misery induced by discontinuing the drug.
'My life exploded,' Horowitz says. His symptoms, which included severe insomnia and dizziness, were so debilitating that he moved back in with his parents. 'It took me years to come off, not weeks as guidelines recommended.'
After he recovered, Horowitz began pushing for doctors to adopt new clinical guidelines for getting off antidepressants. He coauthored the Royal College of Psychiatry's guidance for psychiatric drug cessation and joined the UK's National Health Service as a clinical research fellow. His goal with Outro is to bring the guided tapering methods he has developed to a new patient base in North America.
Goode, Outro's CEO, has a background working in pharmaceuticals and telehealth that includes stints at Novo Nordisk and the psychedelic therapy startup Field Trip Health, now known as Stella. 'People kept asking how to use psychedelics to get off antidepressants,' Goode says, which led him to suspect there might be a substantial swath of the population who wanted help quitting the drugs.
Horowitz and Goode cofounded Outro in 2022 along with another Field Trip alum, Tyler Dyck. The company's small team also includes Adele Framer, the founder of Surviving Antidepressants, a long-running forum where people swap tips on how to taper off this class of medication.
It's a fraught moment to be launching a health startup in the US focused on getting people off psychiatric drugs. The US secretary of health and human services, Robert F. Kennedy Jr., has questioned whether the medications are overprescribed, and has made false claims linking antidepressants to school shootings and increased violence. Similar views have been articulated by other Trumpworld figures, including DOGE architect Elon Musk, who told Tucker Carlson that SSRIs are 'the devil.'
Horowitz says he shares some of Kennedy's concerns about whether antidepressants are overprescribed and how severe withdrawals can be. But he's disturbed that Outro's project could be seen as aligned with the health secretary's broader Make America Healthy Again movement, especially as he considers himself 'to the left of Bernie Sanders.'
'The fact that this has become a political football is really dangerous,' he says. 'These medications have benefits—and they have harms, and can be difficult to stop. My work is about helping people navigate those things in an informed way.'
There is a small but growing group of mental health experts who say it's time to reevaluate how antidepressant withdrawal is understood and treated. Anders Sørenson, a clinical psychologist in Denmark specializing in psychiatric de-prescribing, says the status quo for most patients is 'not just inadequate, but often actively harmful.' He sees an urgent need for more doctors to craft hyperbolic tapering plans customized to each individual patient's needs.
Some psychiatry experts push back on the idea that hyperbolic tapering programs are necessary for many patients. Jonathan E. Alpert, a psychiatrist and professor at Montefiore's Albert Einstein College of Medicine, agrees that taking a thoughtful approach to tapering is important and says hyperbolic tapering 'makes some sense neurobiologically.' But he thinks a large portion of people who want to quit psychiatric drugs can do so by using what he considers to be 'less fussy' methods, like gradually halving doses, rather than relying on 'an extremely precise, extremely elaborate and potentially resource-intensive approach to a problem that usually can be handled in a much more straightforward way.'
Horowitz sees his work with Outro as part of a larger mission to shift the public conversation about the root causes of psychological problems. While he doesn't want to discourage people who need medication from taking it, he believes that the level of chronic SSRI use happening today should be carefully evaluated to ensure social factors contributing to mental health issues are not being overlooked. 'To me, it is actually a very leftist issue to de-medicalize the way we treat anxiety and depression,' he says, noting that such illnesses are often caused 'by social circumstances, by poverty, by loneliness.'
Outro is making the opposite pitch of most online health startups, offering to help people stop drugs rather than start them. But its website doesn't look too different from that of other telehealth companies, featuring the same neutral colors and clean fonts that have come to define the world of direct-to-consumer millennial wellness brands. On its landing page, a chirpy pop-up appears advertising its introductory offer: 'Get started for $99.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
42 minutes ago
- Medscape
Fast Five Quiz: Drowning
Drowning is a significant cause of mortality. In the United States, it is the leading cause of death among children aged 1-4 years. Even when not fatal, drowning can result in permanent and severe disability due to prolonged hypoxia. Globally, drowning deaths decreased by 38% between 2000 and 2024. However, in the United States, the drowning mortality rate increased from 2019 to 2022. On average, 11 drowning deaths per day occur in the United States. Do you know the latest facts surrounding drowning? Check your knowledge with this brief quiz. There are major racial/ethnic disparities in drowning deaths and swimming ability in the United States. Although Alaska Native/non-Hispanic American Indian peoples and Black people have the highest drowning rates, the lowest rate of swimming lessons is among Hispanic adults, at only 28.1%. Comparatively, 36.9% of Black adults and 51.8% of White adults have taken swimming lessons. The overall rate of swimming lessons among all US adults is 45.3%. Learn more about drowning epidemiology. A global review on drowning prevention among children and young people found several effective strategies. In addition to placing barriers around bodies of water, the review also found wearing personal flotation devices and removing or covering water hazards to be effective in drowning prevention. Use of solar pool covers was deemed a harmful strategy because unsupervised children have become trapped under these covers and drowned. There have also been cases of drowning deaths among infants placed in baby bath seats in bathtubs. Community-based water safety awareness campaigns were rated as "promising" in the review. Although several campaigns have resulted in increased rates of personal flotation device ownership, the results vary according to the nature of the campaign and its audience. Some campaigns were noted to lack a statistically significant positive impact. Learn more about patient education on drowning. A retrospective cohort study of 406 pediatric drowning patients found that the absence of prehospital cardiac arrest, along with transfer to a high-volume hospital and indoor drowning location, were factors significantly associated with a good clinical outcome. In the study, only one patient died among the 218 patients without prehospital cardiac arrest. However, only five patients had good outcomes among the 188 patients with prehospital cardiac arrest. Patient sex, age, and prehospital time since drowning event were not significantly associated with clinical outcome. Learn more about drowning prognosis. According to American Heart Association/American Academy of Pediatrics guidelines, in-water rescue breathing should be provided to drowning victims by trained rescuers if safe. Guidelines from the Wilderness Medical Society concur. It is not necessary to wait until the patient is on dry land or in a vessel before commencing rescue breathing. Resuscitation of drowning patients should not focus on chest compressions alone. Ventilation and airway management are crucial because cardiac arrest often follows severe hypoxemia in drowning cases. Although it is prudent for water recreation areas to provide automatic external defibrillators, most drowning victims who enter cardiac arrest do not present with defibrillation-responsive rhythms. The Heimlich maneuver is not recommended in drowning because efforts to expel water from the lungs delays resuscitation and might increase the risk for vomiting and aspiration. Learn more about prehospital care in drowning. The Wilderness Medical Society does not recommend empirical antibiotics in the initial management of drowning patients. Although pneumonia might result from aspirated water, the causative microorganisms are often atypical and unresponsive to empirical antibiotic therapies. Additionally, inflammatory pneumonitis resulting from water aspiration and the stress of the drowning event may be mistaken for symptoms of infectious pneumonia. Ideally, before antibiotic administration, pneumonia should be confirmed by urinary antigen testing, sputum cultures, and/or blood cultures. Learn more about the disposition of drowning victims.
Yahoo
42 minutes ago
- Yahoo
Vertex Presents Positive Data for Zimislecel in Type 1 Diabetes at the American Diabetes Association 85th Scientific Sessions
– Results from the study continue to demonstrate the transformative potential of zimislecel with consistent and durable patient benefit – – All 12 patients with at least one year of follow-up who received a full dose of zimislecel as a single infusion achieved ADA-recommended target HbA1c levels <7% and >70% time-in-range (70-180 mg/dL), and 10/12 patients were insulin free – – Data presented at ADA simultaneously published in the New England Journal of Medicine – – Vertex to host investor webcast tonight, June 20, 2025, at 7:15 p.m. CT / 8:15 p.m. ET – BOSTON, June 20, 2025--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced simultaneous presentation and publication of updated data from the Phase 1/2 portion of the Phase 1/2/3 FORWARD-101 clinical trial of zimislecel (VX-880), an investigational stem cell-derived, fully differentiated islet cell therapy, in people with type 1 diabetes (T1D) with impaired hypoglycemic awareness and severe hypoglycemic events (SHEs). The data were featured in an oral presentation at the American Diabetes Association (ADA) annual conference in Chicago as part of the symposium, "Innovation and Progress in Stem Cell-Derived Islet-Cell Replacement Therapy," from 6:15-6:30 p.m. CT (abstract 2025-A-1921) and published online by the New England Journal of Medicine. The data are from 12 patients who received the full dose of zimislecel as a single infusion and were followed for at least one year, as of October 2024. Results from the study to date continue to demonstrate the transformative potential of zimislecel with consistent and durable patient benefit with longer follow-up. All 12 participants: Demonstrated engraftment with glucose-responsive endogenous C-peptide production, which was durable through one year of follow-up. Achieved the ADA targets of HbA1c <7% and time in range of >70%. Were free of SHEs from day 90 onwards. Had a reduction in exogenous insulin use (mean reduction in daily insulin dose: 92%). 10/12 (83%) no longer required exogenous insulin at Month 12. Achieved the Phase 1/2 primary endpoint of elimination of SHEs with HbA1c <7%. Zimislecel continues to be generally well tolerated. Most adverse events (AEs) were mild or moderate, and there were no serious AEs related to zimislecel treatment. As previously reported, two patient deaths occurred, both unrelated to treatment with zimislecel. The safety profile is generally consistent with the immunosuppressive regimen used in the study, the infusion procedure, and complications from long-standing diabetes. "These data on the first fully differentiated, stem cell-derived, off-the-shelf islet cell therapy continue to be unprecedented. The magnitude, consistency and durability of the results from all 12 patients with more than one year of follow-up reinforce the transformative potential of zimislecel for people living with T1D complicated by severe hypoglycemia," said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer at Vertex. "We are excited to complete enrollment and dosing in the Phase 1/2/3 Program and look forward to potential regulatory submissions next year." "It's remarkable to see 12 out of 12 patients with baseline HbA1c above 7% and multiple severe hypoglycemic events reach consensus targets for glycemic control by both HbA1c and time in range as well as elimination of severe hypoglycemic events," said Michael R. Rickels, M.D., M.S., Medical Director, Pancreatic Islet Cell Transplant Program, Willard and Rhoda Ware Professor in Diabetes and Metabolic Diseases, Presenting Author and Steering Committee Co-Chair for the zimislecel clinical program, and author on the New England Journal of Medicine paper. "As I think about my patients and the unmet need in the type 1 diabetes community, the results we've seen so far for restoring endogenous insulin secretion with a stem cell-derived islet therapy bring me hope and confidence for a transformative treatment option for individuals with type 1 diabetes in the not-so-distant future." About Type 1 DiabetesT1D results from the autoimmune destruction of insulin-producing beta cells in pancreatic islets. Insulin deficiency results in hyperglycemia and can lead to acute life-threatening complications such as diabetic ketoacidosis. People with T1D are reliant on lifelong treatment with exogenous insulin that requires careful monitoring of blood glucose levels. Even with the availability of advanced exogenous insulin delivery and glucose monitoring systems, people with T1D can have periods of very low and very high blood sugar levels. Exogenous insulin has a narrow therapeutic range and carries an inherent risk of causing low blood sugar levels or hypoglycemic events, which can potentially result in arrhythmias, seizures, coma and even death. Due to the limitations and complexities of exogenous insulin treatment, it can be difficult for people with T1D to achieve and maintain good glucose control. Exposure to prolonged periods of high blood glucose levels, or hyperglycemia, can lead to long-term complications such as nerve damage, kidney disease/failure, eye disease (including vision loss), cardiovascular disease, stroke and even death. HbA1c is a measure of average blood glucose over the most recent ~2-3 months, and the consensus guidance is to maintain an HbA1c of <7% to reduce the risk of long-term complications; only ~1 in 4 people with T1D globally meet this clinical target. Current standards of care do not address the underlying cause of the disease and leave people with T1D susceptible to both hypo- and hyperglycemia and their associated morbidity and mortality. There is no cure for T1D. About ZimislecelZimislecel (VX-880) is an investigational allogeneic stem cell-derived, fully differentiated, insulin-producing islet cell therapy manufactured using proprietary technology. Zimislecel is being evaluated for patients who have T1D with impaired hypoglycemic awareness and severe hypoglycemia. Zimislecel has the potential to restore the body's ability to regulate glucose levels by restoring pancreatic islet cell function, including glucose-responsive insulin production. Zimislecel is delivered by an infusion into the hepatic portal vein and requires chronic immunosuppressive therapy to protect the islet cells from immune rejection. The zimislecel trial has expanded to additional sites that are currently active and enrolling in the U.S., Canada and Europe. Zimislecel has been granted Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations from the U.S. Food and Drug Administration, Priority Medicines (PRIME) designation from the European Medicines Agency (EMA), and has secured an Innovation Passport under the Innovative Licensing and Access Pathway (ILAP) from the UK Medicines and Healthcare products Regulatory Agency (MHRA). Zimislecel is investigational and has not been approved by health authorities globally. About VertexVertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases and conditions. The company has approved therapies for cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia and acute pain, and it continues to advance clinical and research programs in these areas. Vertex also has a robust clinical pipeline of investigational therapies across a range of modalities in other serious diseases where it has deep insight into causal human biology, including neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy, primary membranous nephropathy, autosomal dominant polycystic kidney disease, type 1 diabetes and myotonic dystrophy type 1. Vertex was founded in 1989 and has its global headquarters in Boston, with international headquarters in London. Additionally, the company has research and development sites and commercial offices in North America, Europe, Australia, Latin America and the Middle East. Vertex is consistently recognized as one of the industry's top places to work, including 15 consecutive years on Science magazine's Top Employers list and one of Fortune's 100 Best Companies to Work For. For company updates and to learn more about Vertex's history of innovation, visit or follow us on LinkedIn, Facebook, Instagram, YouTube and X. Special Note Regarding Forward-Looking StatementsThis press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, (i) statements by Carmen Bozic, M.D., and Michael R. Rickels, M.D., M.S., in this press release, (ii) plans, expectations for, and the potential benefits of zimislecel, (iii) expectations for the Phase 1/2/3 clinical trial for zimislecel, including expectations for the trial to complete enrollment and dosing, and (iv) plans for potential regulatory submissions next year. While Vertex believes the forward-looking statements contained in this press release are accurate, these forward-looking statements represent the company's beliefs only as of the date of this press release and there are a number of risks and uncertainties that could cause actual events or results to differ materially from those expressed or implied by such forward-looking statements. Those risks and uncertainties include, among other things, that data from a limited number of patients may not be indicative of final clinical trial results, that data from the company's research and development programs may not support registration or further development of its potential medicines in a timely manner, or at all, due to safety, efficacy, that timelines for regulatory submissions may be longer than anticipated, and other risks listed under the heading "Risk Factors" in Vertex's most recent annual report and subsequent quarterly reports filed with the Securities and Exchange Commission at and available through the company's website at You should not place undue reliance on these statements, or the scientific data presented. Vertex disclaims any obligation to update the information contained in this press release as new information becomes available. (VRTX-GEN) Investor Event and Webcast Vertex will host an investor event on Friday, June 20, 2025, at 7:15 p.m. CT/8:15 p.m. ET, in Chicago, to discuss the positive zimislecel data in type 1 diabetes. A live webcast of the presentation and Q&A portions can be accessed through the Investor Relations section of Vertex's website at An archived webcast will be available on the company's website. View source version on Contacts Vertex Pharmaceuticals IncorporatedInvestors: InvestorInfo@ Media: mediainfo@ orInternational: +44 20 3204 5275
CBS News
42 minutes ago
- CBS News
Pennsylvania family who stayed at Ronald McDonald house shares their continued message of hope
Bucks County family who stayed at the Ronald McDonald house shares their continued message of hope Bucks County family who stayed at the Ronald McDonald house shares their continued message of hope Bucks County family who stayed at the Ronald McDonald house shares their continued message of hope "Sarah's Painting" was created in a hospital bed by a 9-year-old going through chemotherapy. Michael Pulaski said his daughter, Sarah, loved to paint. "Which was kind of news to us, and she was actually pretty good!" Michael Pulaski said with a chuckle and smile. "It meant something to her, so it meant something to us." Now this picture is taking on a bigger meaning. "Sarah's Painting" CBS News Philadelphia. "It's been, for years, my method of communicating with the world," Sarah's brother, Ryan Pulaski, said. The 22-year-old college student is in the process of making an album. His first single was released Friday, on what would be Sarah's 25th birthday. "In Sarah's Painting, I see visions of life it should be," he sings in the song called "Sarah's Painting." It's inspired by the colorful brush strokes frozen in time. "I feel exceptionally called to create art, and it is only because I had, I have this wonderful sister who was an artist herself, that I was able to find my own voice," Ryan Pulaski said. Pulaski family. In 2010, CBS News Philadelphia caught Sarah's infectious smile on camera while walking the halls of the Children's Hospital of Philadelphia. She talked with us about a Ronald McDonald house family room for the telethon. "When we first met you, it was actually a stressful but promising time, because Sarah was in her first portions of treatment, and she was doing well," Michael Pulaski said. The pre-teen from Richboro went into remission, but later relapsed. At 11 years old, she died after a brave, long battle with leukemia. "This is my absolute favorite picture of the two of them together," Michael Pulaski said, pointing at a photo of Ryan and Sarah. Pulaski family. It's an unbreakable sibling bond — shining through photos, "Sarah's Painting," and now Ryan's song. "She'd probably tell me, I still can't sing," Ryan Pulaski said with a laugh. He continued, "But I think she would love it and be supportive all the same." As for the sibling's dad, "There aren't words, and I'm just proud." The Pulaski family said this story — it's one full of hope, to show others, a picture is worth a thousand words, a thousand memories and a love that lasts a thousand lifetimes. "I think if my 22-year-old son, who's had a probably a more difficult journey than I have, can find hope and joy, then I think the rest of us can too," Michael Pulaski said.
